tradingkey.logo
tradingkey.logo

Cerus Corp

CERS
View Detailed Chart
1.730USD
-0.050-2.81%
Close 03/30, 16:00ETQuotes delayed by 15 min
94.13MMarket Cap
LossP/E TTM

Cerus Corp

1.730
-0.050-2.81%
Intraday
1m
30m
1h
D
W
M
D

Today

-2.81%

5 Days

-4.95%

1 Month

-31.62%

6 Months

+8.81%

Year to Date

-16.02%

1 Year

+21.83%

View Detailed Chart

TradingKey Stock Score of Cerus Corp

Currency: USD Updated: 2026-03-30

Key Insights

Cerus Corp's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 90 out of 208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 5.00.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Cerus Corp's Score

Industry at a Glance

Industry Ranking
90 / 208
Overall Ranking
216 / 4542
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Negative

Cerus Corp Highlights

StrengthsRisks
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 25.16% year-on-year.
Undervalued
The company’s latest PE is -21.10, at a low 3-year percentile range.
Held by PRFDX
Star Investor PRFDX holds 20.70K shares of this stock.

Analyst Rating

Based on 3 analysts
Buy
Current Rating
5.000
Target Price
+180.90%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Cerus Corp News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Cerus Corp Info

Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
Ticker SymbolCERS
CompanyCerus Corp
CEOGreenman (William M)
Websitehttps://www.cerus.com/
KeyAI